A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients

Trial Profile

A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Letermovir (Primary) ; Letermovir (Primary)
  • Indications Cytomegalovirus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
    • 30 May 2017 According to a Merck & Co media release, data from this trial will be presented at the American Society for Microbiology (ASM) 2017 meeting.
    • 25 Apr 2017 Results assessing the safety and tolerability of letermovir prophylaxis for cytomegalovirus infection in adult CMV-seropositive recipients of allogeneic haematopoietic cell transplantation up to week 24, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top